LEADING THE SMALL MOLECULE FIGHT AGAINST RSV

Driving small molecule antiviral development for Respiratory Syncytial Virus infection

RSV: Serious Unmet Medical Need
  • RSV is a common and serious cause of respiratory infection in children, the immune-compromised and the elderly
  • The World Health Organization (WHO) estimates that RSV causes 64 million infections and 160,000 infant deaths each year
  • It is the most important respiratory virus, responsible for one-fifth of all lower respiratory tract infections worldwide
  • There are no effective treatments or vaccines available against RSV

Leading the Way: Sisunatovir

  • An RSV fusion (F) protein inhibitor
  • Best-in-class drug to treat RSV infections
  • Completed Phase 1 studies with antiviral exposures achieved
  • Completed RSV challenge model with high potency against both viral load and symptoms
  • Excellent safety profile
  • Entering an international multicentre Phase 2 paediatric trial

Meet the Team...
Latest News
ReViral Appoints Lawrence Blatt and Richard N. Kender to its Board of Directors

London, UK, November 27, 2019 – ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing...

Phase 2a Study Published in Antimicrobial Agents and Chemotherapy Shows Potential of Sisunatovir (RV521) to Combat Respiratory Syncytial Virus Infection

London, UK, November 18, 2019 – ReViral Ltd., a clinical-stage company focused on developing novel, antiviral compounds that target respiratory...

ReViral Announces Appointment of Alan Musso as Chief Financial Officer

London, UK, October 21, 2019 – ReViral Ltd., a clinical-stage company focused on developing novel, antiviral compounds that target respiratory...

Contact us...
Privacy Policy